Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | FPR2 | P25090 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2233475 | 0.88 | KMT2A (0.55) | KMT2AGLACNR1FPR2ATM | |
| SCHEMBL916707 | 0.84 | KMT2A (0.46) | KMT2AMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17916743 | 0.81 | RAB9A (0.69) | KMT2ACNR1FPR2ATMMAPT | |
| SCHEMBL16562164 | 0.78 | RAB9A (0.67) | KMT2ACNR1FPR2ATMMAPT | |
| SCHEMBL637257 | 0.76 | NPC1 (0.54) | KMT2AMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL916705 | 0.75 | UTS2R (0.44) | MAPTNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL637671 | 0.72 | TAAR1 (0.47) | KMT2AMAPTALDH1A1MEN1HPGD | |
| SCHEMBL16562294 | 0.72 | KMT2A (0.70) | KMT2ACNR1FPR2MAPTNPC1 | |
| SCHEMBL3452433 | 0.72 | POLB (0.68) | SMN1; SMN2POLB | |
| SCHEMBL16562203 | 0.72 | CNR1 (0.63) | KMT2ACNR1FPR2ATMNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660440-B1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT INC (US) | 2012-02-22 | — | — | EP | disclosed |
| US-7572830-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20080096960-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. | 2008-04-24 | — | — | US | disclosed |
| EP-1660440-A2 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | Xenoport, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005019163-A2 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096960-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | APEH, ABAT, SI | KMT2A 2442/4885GLA 1307/4885CNR1 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.